Publications by authors named "M Ighilahriz"
Purpose: Vismodegib is approved for the treatment of locally advanced basal cell carcinoma (laBCC), but some cases demonstrate intrinsic resistance (IR) to the drug. We sought to assess the frequency of IR to vismodegib in laBCC and its underlying genomic mechanisms.
Experimental Design: Response to vismodegib was evaluated in a cohort of 148 laBCC patients.